180 related articles for article (PubMed ID: 36006441)
1. Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma.
Girgis S; Wang Lin SX; Pillarisetti K; Verona R; Vieyra D; Casneuf T; Fink D; Miao X; Chen Y; Stephenson T; Banerjee A; Hilder BW; Russell J; Infante J; Elsayed Y; Smit J; Goldberg JD
Blood Adv; 2023 Feb; 7(4):644-648. PubMed ID: 36006441
[No Abstract] [Full Text] [Related]
2. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
Usmani SZ; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Rosinol L; Chari A; Bhutani M; Karlin L; Benboubker L; Pei L; Verona R; Girgis S; Stephenson T; Elsayed Y; Infante J; Goldberg JD; Banerjee A; Mateos MV; Krishnan A
Lancet; 2021 Aug; 398(10301):665-674. PubMed ID: 34388396
[TBL] [Abstract][Full Text] [Related]
3. Subsequent anti-myeloma therapy after maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) treatment in patients with relapsed/refractory multiple myeloma.
Chen D; Wang X; Chen Z; Jiang S; Jiang H; Fu W; Xiang F; Sun X; Du J
Am J Hematol; 2022 Dec; 97(12):E478-E481. PubMed ID: 36197023
[No Abstract] [Full Text] [Related]
4. Real-world analysis of teclistamab in 123 RRMM patients from Germany.
Riedhammer C; Bassermann F; Besemer B; Bewarder M; Brunner F; Carpinteiro A; Einsele H; Faltin J; Frenking J; Gezer D; Goldman-Mazur S; Hänel M; Hoegner M; Kortuem KM; Krönke J; Kull M; Leitner T; Mann C; Mecklenbrauck R; Merz M; Morgner A; Nogai A; Raab MS; Teipel R; Wäsch R; Rasche L
Leukemia; 2024 Feb; 38(2):365-371. PubMed ID: 38245601
[TBL] [Abstract][Full Text] [Related]
5. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
Granger K; Gaffney KJ; Davis JA
J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940
[TBL] [Abstract][Full Text] [Related]
6. A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed/refractory multiple myeloma: results from phase I clinical trials.
Yang M; Zhang W; Yu K; Wang P; Jiang H; Chen L; Meng H; Weng Y; Tao R; Huang X; Xing C; Wang H; Wan J; Wang S; Dai L; Hendrix AY; Xiao J; Wang W; Ma H; Hao S; Jin J; Li Z; Jiang S
Haematologica; 2022 Aug; 107(8):1960-1965. PubMed ID: 35443566
[No Abstract] [Full Text] [Related]
7. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting.
Zhao J; Ren Q; Liu X; Guo X; Song Y
J Hematol Oncol; 2023 Aug; 16(1):92. PubMed ID: 37537597
[TBL] [Abstract][Full Text] [Related]
8. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.
Feng D; Sun J
Scand J Immunol; 2020 Aug; 92(2):e12910. PubMed ID: 32471019
[TBL] [Abstract][Full Text] [Related]
9. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma.
Pillarisetti K; Powers G; Luistro L; Babich A; Baldwin E; Li Y; Zhang X; Mendonça M; Majewski N; Nanjunda R; Chin D; Packman K; Elsayed Y; Attar R; Gaudet F
Blood Adv; 2020 Sep; 4(18):4538-4549. PubMed ID: 32956453
[TBL] [Abstract][Full Text] [Related]
10. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
11. CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma.
Firestone RS; McAvoy D; Shekarkhand T; Serrano E; Hamadeh I; Wang A; Zhu M; Qin WG; Patel D; Tan CR; Hultcrantz M; Mailankody S; Hassoun H; Shah US; Korde N; Maclachlan KH; Landau HJ; Scordo M; Shah GL; Lahoud OB; Giralt S; Murata K; Hosszu KK; Chung DJ; Lesokhin AM; Usmani SZ
Blood Adv; 2024 Apr; 8(7):1600-1611. PubMed ID: 37878808
[TBL] [Abstract][Full Text] [Related]
12. CAR T-cell therapy for triple-class exposed relapsed/refractory multiple myeloma.
Cavo M
Haematologica; 2023 Aug; 108(8):1988-1990. PubMed ID: 37021536
[No Abstract] [Full Text] [Related]
13. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN
J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997
[TBL] [Abstract][Full Text] [Related]
14. Teclistamab: Mechanism of action, clinical, and translational science.
Guo Y; Quijano Cardé NA; Kang L; Verona R; Banerjee A; Kobos R; Chastain K; Uhlar C; Pillarisetti K; Doyle M; Smit J; Haddish-Berhane N; Ouellet D
Clin Transl Sci; 2024 Jan; 17(1):e13717. PubMed ID: 38266057
[TBL] [Abstract][Full Text] [Related]
15. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.
Wang D; Wang J; Hu G; Wang W; Xiao Y; Cai H; Jiang L; Meng L; Yang Y; Zhou X; Hong Z; Yao Z; Xiao M; Chen L; Mao X; Zhu L; Wang J; Qiu L; Li C; Zhou J
Blood; 2021 May; 137(21):2890-2901. PubMed ID: 33512480
[TBL] [Abstract][Full Text] [Related]
16. Real-world applicability of commercial chimeric antigen receptor T-cell therapy among older adults with relapsed and/or refractory multiple myeloma.
Giri S; Bal S; Godby KN; Ravi G; Clark D; Ubersax C; Cooley A; White P; Rangarajan S; Williams GR; Costa LJ
Am J Hematol; 2022 Apr; 97(4):E153-E155. PubMed ID: 35045201
[No Abstract] [Full Text] [Related]
17. Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation.
Frerichs KA; Verkleij CPM; Mateos MV; Martin TG; Rodriguez C; Nooka A; Banerjee A; Chastain K; Perales-Puchalt A; Stephenson T; Uhlar C; Kobos R; van der Holt B; Kruyswijk S; Kuipers MT; Groen K; Vishwamitra D; Skerget S; Cortes-Selva D; Doyle M; Zaaijer HL; Zweegman S; Verona RI; van de Donk NWCJ
Blood Adv; 2024 Jan; 8(1):194-206. PubMed ID: 38052042
[TBL] [Abstract][Full Text] [Related]
18. Talquetamab in multiple myeloma.
Liu L; Krishnan A
Haematologica; 2024 Mar; 109(3):718-724. PubMed ID: 37855056
[TBL] [Abstract][Full Text] [Related]
19. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study.
Nooka AK; Rodriguez C; Mateos MV; Manier S; Chastain K; Banerjee A; Kobos R; Qi K; Verona R; Doyle M; Martin TG; van de Donk NWCJ
Cancer; 2024 Mar; 130(6):886-900. PubMed ID: 37960969
[TBL] [Abstract][Full Text] [Related]
20. Teclistamab: First Approval.
Kang C
Drugs; 2022 Nov; 82(16):1613-1619. PubMed ID: 36352205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
